CSF1 Restores Innate Immunity After Liver Injury in Mice and Serum Levels Indicate Outcomes of Patients With Acute Liver Failure
View abstract on PubMed
Summary
This summary is machine-generated.Low serum levels of macrophage colony-stimulating factor (CSF1) indicate poor prognosis in acute liver injury patients. CSF1 administration enhances liver regeneration and innate immunity in mice, suggesting therapeutic potential.
Area Of Science
- Immunology
- Hepatology
- Regenerative Medicine
Background
- Liver regeneration relies on functional liver macrophages, crucial for immune barrier integrity.
- Liver injury compromises this immune barrier, necessitating understanding of macrophage regulation.
- Macrophage numbers are primarily controlled by macrophage colony-stimulating factor (CSF1).
Purpose Of The Study
- To investigate the prognostic value of serum CSF1 levels in acute liver injury patients.
- To explore the therapeutic effects of CSF1 on liver regeneration and innate immunity in a murine model.
Main Methods
- Serum CSF1 levels were measured in patients with partial hepatectomy and acetaminophen-induced acute liver failure.
- CSF1-Fc was administered to mice after partial hepatectomy and acetaminophen intoxication.
- Hepatic macrophage dynamics, regenerative parameters, and innate immunity were assessed in mice.
Main Results
- Serum CSF1 levels correlated with the extent of liver resection in surgical patients.
- Low serum CSF1 was linked to increased mortality in acute liver failure patients.
- CSF1 administration in mice promoted hepatic macrophage proliferation and monocyte differentiation, enhancing innate immunity post-injury.
Conclusions
- Serum CSF1 serves as a prognostic biomarker for acute liver injury.
- CSF1 demonstrates potential as a therapeutic agent to bolster innate immune function following liver damage.